{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T08:28:40Z","timestamp":1781857720225,"version":"3.54.5"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chan Zuckerberg Biohub, United States"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Auto-antibodies (Abs) to type I interferons (IFNs) are found in up to 25% of patients with severe COVID-19, and are implicated in disease pathogenesis. It has remained unknown, however, whether type I IFN auto-Abs are unique to COVID-19, or are also found in other types of\u00a0severe respiratory illnesses. To address this, we studied a prospective cohort of 284 adults with acute respiratory failure due to causes other than COVID-19. We measured type I IFN auto-Abs by radio ligand binding assay and screened for respiratory viruses using clinical PCR and metagenomic sequencing. Three patients (1.1%) tested positive for type I IFN auto-Abs, and each had a different underlying clinical presentation. Of the 35 patients found to have viral infections, only one patient tested positive for type I IFN auto-Abs. Together, our data suggest that type I IFN auto-Abs are uncommon in critically ill patients with acute respiratory failure due to causes other than COVID-19.\n<\/jats:p>","DOI":"10.1186\/s12931-022-02283-4","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T15:03:22Z","timestamp":1671203002000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Prevalence of type-1 interferon autoantibodies in adults with non-COVID-19 acute respiratory failure"],"prefix":"10.1186","volume":"23","author":[{"given":"Rajani","family":"Ghale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Spottiswoode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthea","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.","family":"Calfee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"DeRisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles R.","family":"Langelier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,16]]},"reference":[{"key":"2283_CR1","doi-asserted-by":"publisher","first-page":"eabd4585","DOI":"10.1126\/science.abd4585","volume":"370","author":"P Bastard","year":"2020","unstructured":"Bastard P, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370:eabd4585.","journal-title":"Science"},{"key":"2283_CR2","doi-asserted-by":"publisher","first-page":"eabh2624","DOI":"10.1126\/scitranslmed.abh2624","volume":"13","author":"MGP van der Wijst","year":"2021","unstructured":"van der Wijst MGP, et al. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci Transl Med. 2021;13:eabh2624.","journal-title":"Sci Transl Med"},{"key":"2283_CR3","doi-asserted-by":"publisher","first-page":"eabl4340","DOI":"10.1126\/sciimmunol.abl4340","volume":"6","author":"P Bastard","year":"2021","unstructured":"Bastard P, et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021;6:eabl4340.","journal-title":"Sci Immunol"},{"key":"2283_CR4","doi-asserted-by":"crossref","unstructured":"Goncalves D. et al. Antibodies against type I interferon: detection and association with severe clinical outcome in COVID\u201019 patients. Clin Transl Immunol. 2021;10.","DOI":"10.1002\/cti2.1327"},{"key":"2283_CR5","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20210554","volume":"218","author":"P Bastard","year":"2021","unstructured":"Bastard P, et al. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J Exp Med. 2021;218: e20210554.","journal-title":"J Exp Med"},{"key":"2283_CR6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1809700115","author":"C Langelier","year":"2018","unstructured":"Langelier C, et al. Integrating host response and unbiased microbe detection for lower respiratory tract infection diagnosis in critically ill adults. Proc Natl Acad Sci USA. 2018. https:\/\/doi.org\/10.1073\/pnas.1809700115.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2283_CR7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1046\/j.1365-2249.2003.02113.x","volume":"132","author":"A Meager","year":"2003","unstructured":"Meager A, et al. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and\/or myasthenia gravis. Clin Exp Immunol. 2003;132:128\u201336.","journal-title":"Clin Exp Immunol"},{"key":"2283_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1159\/000508379","volume":"12","author":"W Wu","year":"2020","unstructured":"Wu W, Metcalf JP. The role of type I IFNs in influenza: antiviral superheroes or immunopathogenic villains? J Innate Immun. 2020;12:437\u201347.","journal-title":"J Innate Immun"},{"key":"2283_CR9","doi-asserted-by":"publisher","first-page":"5152","DOI":"10.1038\/s41467-021-25040-5","volume":"12","author":"A Sarma","year":"2021","unstructured":"Sarma A, et al. Tracheal aspirate RNA sequencing identifies distinct immunological features of COVID-19 ARDS. Nat Commun. 2021;12:5152.","journal-title":"Nat Commun"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-02283-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-022-02283-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-02283-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T15:05:45Z","timestamp":1671203145000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-022-02283-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,16]]},"references-count":9,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2283"],"URL":"https:\/\/doi.org\/10.1186\/s12931-022-02283-4","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,16]]},"assertion":[{"value":"13 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and consent to participate was obtained from the UCSF Institutional Review Board protocol according to protocol number 17-24056, as described in detail previously [].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent to publish was obtained from the UCSF Institutional Review Board protocol according to protocol number 17-24056.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"354"}}